ストックスクリーナーアプリを入手
59.22
2.09%
1.215
前日終値:
$58.01
開ける：
$58.28
24時間の取引高:
689.82K
Relative Volume:
2.00
時価総額：
$1.21B
収益：
$1.77M
当期純損益:
$-123.74M
株価収益率:
-6.458
EPS:
-9.17
ネットキャッシュフロー:
$-95.21M
1週間 パフォーマンス:
+9.97%
1か月 パフォーマンス:
+36.67%
6か月 パフォーマンス:
-23.20%
1年 パフォーマンス:
+2.92%
1日の値動き範囲:
$56.66
$61.03
1週間の範囲:
$53.88
$61.03
52週間の値動き範囲:
$26.70
$91.83
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
名前
Praxis Precision Medicines Inc
セクター
電話
617-300-8460
住所
99 HIGH STREET, 30TH FLOOR, BOSTON
PRAX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
59.22 | 1.18B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-05-07 | 開始されました | Chardan Capital Markets | Buy |
| 2025-03-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-08-05 | 開始されました | Oppenheimer | Outperform |
| 2024-06-24 | 開始されました | Needham | Buy |
| 2024-06-18 | 開始されました | Guggenheim | Buy |
| 2024-05-01 | 開始されました | Robert W. Baird | Outperform |
| 2023-09-19 | 開始されました | Truist | Buy |
| 2022-06-06 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2021-08-26 | 開始されました | BofA Securities | Buy |
| 2021-04-26 | 開始されました | William Blair | Outperform |
| 2020-11-11 | 開始されました | Wedbush | Outperform |
| 2020-11-10 | 開始されました | Cowen | Outperform |
| 2020-11-10 | 開始されました | Evercore ISI | Outperform |
| 2020-11-10 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Praxis Precision Medicines Inc (PRAX) 最新ニュース
What analysts say about Praxis Precision Medicines Inc. stock outlookFree Market Volatility Navigation Tips - jammulinksnews.com
Why Praxis Precision Medicines Inc. stock attracts strong analyst attentionGroup Only Stock Signals - Newser
Will Praxis Precision Medicines Inc. stock benefit from AI tech trendsPhenomenal capital gains - jammulinksnews.com
What makes Praxis Precision Medicines Inc. stock price move sharplyShort Squeeze Radar - Newser
Praxis Precision Medicines Inc. Stock Analysis and ForecastTremendous return on equity - Autocar Professional
Is Praxis Precision Medicines Inc. a good long term investmentExceptional profit potential - PrintWeekIndia
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
What drives Praxis Precision Medicines Inc. stock priceConsistent triple-digit returns - jammulinksnews.com
What analysts say about Praxis Precision Medicines Inc. stockBreakthrough capital growth - jammulinksnews.com
Major Depressive Disorder Clinical Trials, Companies, - openPR.com
Does Praxis Precision Medicines Inc. stock pay reliable dividendsShort Squeeze Radar - Newser
Praxis Precision Medicines’ (PRAX) Buy Rating Reiterated at HC Wainwright - Defense World
(PRAX) Trading Report - news.stocktradersdaily.com
Here's Why We're Not Too Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Situation - 富途牛牛
Praxis Precision Medicines stock gets BTD for relutrigine, H.C. Wainwright maintains Buy - Investing.com Nigeria
Praxis Precision Medicines stock gets BTD for relutrigine, H.C. Wainwright maintains Buy By Investing.com - Investing.com South Africa
PRAX: HC Wainwright & Co. Reiterates Buy Rating with $105 Target - GuruFocus
Praxis Precision gets FDA breakthrough therapy status for Relutrigine - Seeking Alpha
FDA grants breakthrough therapy designation to Praxis’ relutrigine for pediatric epilepsy - Investing.com Canada
Q1 Earnings Forecast for PRAX Issued By HC Wainwright - Defense World
Praxis Precision Medicines and the Breakthrough Potential of Relutrigine in Rare Epilepsy Therapies: Strategic and Financial Implications of FDA Breakthrough Therapy Designation - AInvest
Praxis Says FDA Grants Breakthrough Therapy Designation To Relutrigine For Rare Pediatric Epilepsies - Nasdaq
FDA grants breakthrough therapy status to Praxis’s relutrigine By Investing.com - Investing.com Canada
FDA grants breakthrough therapy status to Praxis’s relutrigine - Investing.com Australia
Praxis Precision Medicines Gains FDA Breakthrough Designation - TipRanks
Praxis Precision Medicines Inc (PRAX) 財務データ
収益
当期純利益
現金流量
EPS
Praxis Precision Medicines Inc (PRAX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 14 '24 |
Sale |
80.20 |
8,239 |
660,827 |
10,301 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Option Exercise |
56.94 |
4,374 |
249,056 |
10,801 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Sale |
81.78 |
5,188 |
424,318 |
5,613 |
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):